S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:VRAX

Virax Biolabs Group (VRAX) Competitors

$0.38
0.00 (0.00%)
(As of 06/6/2023 ET)
Compare
Today's Range
$0.38
$0.40
50-Day Range
$0.34
$0.70
52-Week Range
$0.34
$29.00
Volume
126,300 shs
Average Volume
238,227 shs
Market Capitalization
$5.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VRAX vs. LHDXQ, LHDX, NAVB, CDIO, SNPX, PHIO, OGEN, AVGR, NBSE, and IGAP

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Lucira Health (LHDXQ), Lucira Health (LHDX), Navidea Biopharmaceuticals (NAVB), Cardio Diagnostics (CDIO), Synaptogenix (SNPX), Phio Pharmaceuticals (PHIO), Oragenics (OGEN), Avinger (AVGR), NeuBase Therapeutics (NBSE), and Integrity Applications (IGAP). These companies are all part of the "medical" sector.

Virax Biolabs Group vs.

Virax Biolabs Group (NASDAQ:VRAX) and Lucira Health (NASDAQ:LHDXQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability.

In the previous week, Virax Biolabs Group had 2 more articles in the media than Lucira Health. MarketBeat recorded 2 mentions for Virax Biolabs Group and 0 mentions for Lucira Health. Virax Biolabs Group's average media sentiment score of 0.00 equaled Lucira Health's average media sentiment score.

Company Overall Sentiment
Virax Biolabs Group Neutral
Lucira Health Neutral

0.5% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 57.0% of Lucira Health shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 30.4% of Lucira Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Virax Biolabs Group has higher earnings, but lower revenue than Lucira Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virax Biolabs Group$5.76 thousand1,036.47-$1.71 millionN/AN/A
Lucira Health$93.06 million0.02-$64.83 million-$3.58-0.02

Virax Biolabs Group and Lucira Health both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
Virax Biolabs GroupN/AN/A
Lucira HealthN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Lucira Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Virax Biolabs Group has a net margin of 0.00% compared to Lucira Health's net margin of -67.54%. Virax Biolabs Group's return on equity of 0.00% beat Lucira Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Virax Biolabs Group N/A N/A N/A
Lucira Health -67.54% -13.55% -8.47%

Summary

Virax Biolabs Group beats Lucira Health on 7 of the 9 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAX vs. The Competition

MetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$5.97M$2.35B$4.54B$6.30B
Dividend YieldN/A0.79%5.90%6.52%
P/E RatioN/A72.63128.1114.85
Price / Sales1,036.47698.233,489.7396.83
Price / CashN/A37.6322.5223.57
Price / BookN/A6.004.745.39
Net Income-$1.71M$28.14M$117.08M$192.60M
7 Day Performance-1.54%-0.51%4.78%3.72%
1 Month Performance9.37%0.12%2.60%5.11%
1 Year PerformanceN/A-11.29%15.51%2.99%

Virax Biolabs Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LHDXQ
Lucira Health
0 of 5 stars
$0.08
-32.5%
N/AN/A$3.37M$93.06M-0.02N/AUpcoming Earnings
Gap Down
LHDX
Lucira Health
0 of 5 stars
$0.08
-32.5%
N/A-96.8%$3.33M$212.13M-0.02114Gap Down
NAVB
Navidea Biopharmaceuticals
0 of 5 stars
$0.09
flat
N/AN/A$3.17M$70,000.00-0.18N/AGap Down
High Trading Volume
CDIO
Cardio Diagnostics
1.9939 of 5 stars
$1.54
+4.8%
$8.00
+419.5%
N/A$14.94MN/A0.00N/AGap Down
SNPX
Synaptogenix
0 of 5 stars
$0.82
-3.5%
N/A-86.8%$6.05MN/A-0.404Positive News
Gap Up
PHIO
Phio Pharmaceuticals
0 of 5 stars
$4.03
-0.2%
N/A+310.6%$6.05MN/A0.0012
OGEN
Oragenics
0 of 5 stars
$2.98
-2.0%
N/AN/A$6.02M$130,000.000.00N/A
AVGR
Avinger
1.6384 of 5 stars
$0.56
flat
N/A-65.4%$6.00M$8.27M-0.1868
NBSE
NeuBase Therapeutics
2.0703 of 5 stars
$0.18
flat
$8.50
+4,724.1%
-81.4%$5.96MN/A-0.2333Gap Up
IGAP
Integrity Applications
0 of 5 stars
$0.41
flat
N/A-87.0%$6.27MN/A0.0011Gap Up
High Trading Volume

Related Companies and Tools

This page (NASDAQ:VRAX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -